

Last Close 0.17 (AUD)	Avg Daily Vol 1.8M	52-Week High 0.19	Trailing PE --	Annual Div --	ROE -35.0%	LTG Forecast --	1-Mo Return 3.0%
11 November, 2015 AUSTRALIAN Exchange	Market Cap 65M	52-Week Low 0.07	Forward PE --	Dividend Yield --	Annual Rev 0M	Inst Own 2.7%	3-Mo Return 47.8%


AVERAGE SCORE

NEUTRAL OUTLOOK: OSL's current score is relatively in-line with the market.

AVERAGE
SCORE

5
Score Averages

Biotech & Med. Research Group: 4.5	Micro Market Cap: 4.3
Pharma. & Med. Research Sector: 4.8	ASX 200 Index: 7.1

Average Score Trend (4-Week Moving Avg)


Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
ADO	1	3	5	4	5	
OBJ	5	6	6	6	5	
OSL	4	4	4	4	5	
NRT	5	3	3	3	4	
BLT	4	6	3	3	3	




HIGHLIGHTS

- The score for Oncosil Medical reached 5 this week, its best value over the past year.
- The recent change in Average Score was due to relative changes in other companies within the market as a comparison, even though the underlying component scores did not improve for this company.

THOMSON REUTERS I/B/E/S MEAN
Strong Buy

2 Analysts

Mean recommendation from all analysts covering the company on a standardized 5-point scale.



PRICE AND VOLUME CHARTS
1-Year Return: 47.8%

5-Year Return: 325.0%

BUSINESS SUMMARY

Oncosil Medical Limited is an Australia-based biotechnology development company focused on the radiotherapy technology for the treatment of cancer. The Company's core technology includes the application of radioactive phosphorus (P32) to patients to control tumor growth. The Company along with a German radio pharmaceutical and nuclear medicine company, Eckert & Ziegler, is engaged in the manufacture of OncoSil. Its lead product OncoSil is a class III implantable nuclear medical device that emits radiation locally into a tumor and is in late stage clinical research. OncoSil is a bio-silica P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment to control tumor growth. OncoSil device delivers localized beta radiation and is used in other solid tumors outside of pancreatic cancer. The Company's subsidiaries include Enigma Therapeutics Limited, United Kingdom; OncoSil Medical Germany GmbH, Germany, and OncoSil Medical US Inc., United States.



INDICATOR COMPONENTS
**AVERAGE
SCORE**
5

The **AVERAGE SCORE** combines the quantitative analysis of five widely-used investment decision making tools: Earnings, Fundamental, Relative Valuation, Risk, and Price Momentum. A simple average of the underlying component ratings is normally distributed to rank stocks on a 1-10 scale (10 being awarded to the most favorable). These factors may be evaluated differently using alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.


PEER ANALYSIS

Currency in AUD

		PRICE MOMENTUM					VALUATION		FUNDAMENTAL		ANALYSTS		
Average Score	Ticker	Price (11/11/15)	1-Mo Return	3-Mo Return	1-Yr Return	Market Cap	Trailing PE	Forward PE	Dividend Yield	Net Margin	LTG Forecast	I/B/E/S Mean	# of Analysts
4	SPL	0.74	-2.0%	8.0%	23.3%	232M	--	--	--	-1117%	--	Buy	3
7	VLA	0.66	6.5%	-2.9%	127.6%	125M	--	--	--	-142.7%	--	Buy	3
3	PRR	0.05	-12.3%	8.7%	31.6%	107M	--	--	--	-1536%	--	--	--
5	OBJ	0.05	-3.6%	-26.0%	-43.2%	92M	--	--	--	-155.3%	--	--	--
5	ADO	0.09	-12.0%	-12.0%	-23.5%	80M	--	--	--	-907.3%	--	--	--
5	OSL	0.17	3.0%	47.8%	47.8%	65M	--	--	--	-1891%	--	Strong Buy	2
4	NRT	0.14	-6.7%	-24.3%	17.7%	64M	--	--	--	-7997%	--	--	--
3	BLT	0.41	-14.6%	-46.8%	-51.5%	62M	--	0.9	--	-338.6%	--	Buy	1
3	PBT	0.12	-11.5%	-23.3%	-42.5%	61M	--	--	--	-3328%	--	--	--
4	PNV	0.15	0.0%	45.0%	52.6%	59M	--	--	--	-925.6%	--	--	--
5	AVH	0.10	-17.4%	26.7%	-5.0%	56M	--	--	--	-258.4%	--	--	--
4.4	Average	0.24	-6.4%	0.1%	12.3%	91M	--	0.9	--	-1691%	--	Buy	2.3

PEER COMPANIES

SPL	Starpharma Holdings	NRT	Novogen
VLA	Viralytics	BLT	Benitec Biopharma
PRR	Prima BioMed	PBT	Prana Biotechnology
OBJ	OBJ	PNV	Polynovo
ADO	Anteo Diagnostics	AVH	Avita Medical

